2 results
Approved WMORecruiting
To compare effectiveness, costs and patient preferences in the treatment of sBCC with fractionated 5-ALA 20% PDT versus MAL PDT in 2 sessions.
Approved WMORecruiting
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…